CTLA4 and metastatic melanoma: The current standard of care for patients with metastatic melanoma is a combined therapy with cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody ipilimumab and programmed cell death protein (PD-1) antibody nivolumab, with 5-year OS rates of 52% [3].